Quantiscope PBC

Quantiscope PBC develops an AI-powered enterprise platform called phenotypIQ that automates biological quantification to support preclinical drug discovery and research. By applying machine learning and computer vision to microscopic images, the platform converts high-content biological imaging into actionable phenotypic data. This technology mirrors facial recognition methods, analyzing approximately 1,500 nodes of a cell to model cellular responses to various treatments, including small molecules, biologics, and genetic therapies. The cloud-based, plug-and-play solution is designed to integrate seamlessly into existing therapeutic pipelines, enabling researchers to conduct automated hit identification, enhance optimization, and improve decision-making regarding efficacy and toxicity.

The platform aims to streamline the drug development process, offering significant value to researchers by simplifying data interpretation and reducing the time required for clinical candidate selection. By democratizing access to advanced phenotypic modeling, Quantiscope supports diverse applications ranging from rare disease research to pandemic responsiveness and biodefense. Founded in 2022 and incubated at Altitude Lab, the company has engaged in pilot studies with various biotech and pharmaceutical partners, utilizing its SaaS-based tools to de-risk development and drive innovations in life sciences and biomanufacturing.